16 completed, 8 recruiting, 4 not yet recruiting, 3 terminated. 7 Not applicable, 3 Phase 1, 3 Phase 2, 3 Phase 3, 2 Phase 4.
Follow Age-Related Macular Degeneration (AMD): new trials by email Literature Review of Age-Related Macular Degeneration (AMD) trials Research Report on Age-Related Macular Degeneration (AMD)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MIND-AMD Study: a Multidisciplinary Investigation of Neuroretinal Damage in Age-related Macular Degeneration. Age-Related (Dry) Macular Degeneration, Age-Related Macular Degeneration (AMD) | Not yet recruiting | IRCCS San Raffaele | 160 | 2027-01-02 | 2026-09-29 | |
| Prevalence of Age-Related Macular Degeneration in Assiut University Hospitals OCT - clear - Age-Related Macular Degeneration (AMD) | Not yet recruiting | Assiut University | 90 | 2027-01-01 | 2026-10-21 | |
| Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections Chloroprocaine Ophthalmic Gel 3% (IHEEZO), Sham Subconjunctival Injection, Proparacaine Hydrochloride Ophthalmic Solution 0.5% - Diabetic Macular Edema (DME), Age-Related Macular Degeneration (AMD) | Phase 4 | Enrolling by invitation | Harrow Inc | 236 | 2026-03-31 | 2026-04-07 |
| Long-Term Follow Up of VOY-101 Non-nAMD Extension Study observational study, VOY-101 - Age-Related Macular Degeneration (AMD), Non-Neovascular Age-Related Macular Degeneration | Enrolling by invitation | Perceive Biotherapeutics, Inc. | 88 | 2026-03-03 | 2026-06-22 | |
| High-throughput Large-model-based AI-assisted Diagnosis Using OCT No intervention - Diabetic Retinopathy (DR), Retinal Vein Occlusion (RVO) | Not yet recruiting | Peking Union Medical College Hospital | 2000 | 2025-11-30 | 2025-11-25 | |
| Artificial Intelligence-Aided Screening for Patients With Diabetic Retinopathy and Age-related Macular Degeneration in Family Medicine and Geriatric Medicine Outpatient Clinics VeriSee AI-assisted screening tools for diabetic retinopathy and age-related macular degeneration, Standard fundus photography with physician interpretation - Age-Related Macular Degeneration (AMD), Diabetic Retinopathy (DR) | Not applicable | Recruiting | National Taiwan University Hospital | 4300 | 2025-10-02 | 2026-07-22 |
| EarLy Treatment Response in nEoVascular Macular Degeneration With Eylea 8mg: ELEV8 A Prospective Observational Open Label Study Investigating the Fluid Dynamics During Early Response to Aflibercept 8mg in Patients With Exudative Age-related Macular Degeneration (AMD). treatment with Aflibercept 8mg (Eylea) - Age-Related Macular Degeneration (AMD) | Recruiting | Insel Gruppe AG, University Hospital Bern | 50 | 2025-07-14 | 2026-02-27 | |
| Effectiveness and Cost-Effectiveness Evaluations of AI-Assisted Diagnostic Software (VeriSee) for Ophthalmic Disease Screening The VeriSee AI-assisted diagnostic system, Data collection from the patient's clinical history - Age-Related Macular Degeneration (AMD), Diabetic Retinopathy (DR) | Not applicable | Recruiting | National Taiwan University Hospital | 1000 | 2025-06-02 | 2026-07-22 |
| Study of JMKX003948 Ophthalmic Suspension in Healthy Participants JMKX003948 Ophthalmic Suspension, Placebo - Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME) | Phase 1 | Not yet recruiting | Jemincare | 40 | 2025-02-01 | 2025-02-18 |
| A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy Pozelimab, Cemdisiran, Placebo - Age-related Macular Degeneration (AMD), Geographic Atrophy (GA) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 975 | 2024-10-30 | 2026-10-13 |
| Pivotal Trial of an Automated AI-based System for Early Diagnosis and Prediction of Late Age-related Macular Degeneration No intervention. - Age-related Macular Degeneration (AMD) | Recruiting | iHealthScreen Inc | 1076 | 2024-08-01 | 2025-08-28 | |
| The Efficacy of Home OCT Supported Management in Patients Diagnosed With Neovascular-AMD and Undergoing a Drug Switch to Faricimab Home Optical Coherence Tomography (Home OCT) - Age-Related Macular Degeneration (AMD), Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD | Completed | Rabin Medical Center | 12 | 2024-07-03 | 2026-09-01 | |
| Proteomic Biomarker Identification in Age-Related Macular Degeneration, Diabetic Retinopathy and Retinal Detachment Biological Sample Collection - Age-Related Macular Degeneration (AMD), Diabetic Retinopathy (DR) | Not applicable | Recruiting | Fondazione G.B. Bietti, IRCCS | 260 | 2024-01-24 | 2026-06-02 |
| Rehabilitating Vision Loss in Veterans With Age-Related Macular Degeneration Study-specific rehabilitation (SSR) procedures - Age-related Macular Degeneration (AMD) | Withdrawn | VA Office of Research and Development | 2024-01-01 | 2026-10-05 | ||
| Prevalence and Determinants of Shoulder Girdle Musculoskeletal Complaints in Geriatric Patients With Diminished Vision Visual Impairment, Age-Related Macular Degeneration (AMD) | Completed | Beni-Suef University | 100 | 2023-09-01 | 2025-10-03 | |
| Long-Term Analysis of DImethyl Fumarate, to Slow the Growth of Areas of Geographic Atrophy Dimethyl Fumarate (TECFIDERA™), No active : no treatment - Age-related Macular Degeneration (AMD) | Phase 2 | Recruiting | Assistance Publique - Hôpitaux de Paris | 90 | 2022-02-07 | 2026-02-04 |
| Efficacy and Safety of Brolucizumab 6mg in a Treat and Extend Regimen in Patients With Neovascular Age-Related Macular Degeneration (nAMD) With Prior Anti-VEGF Exposure (PEREGRINE) brolucizumab - Age-related Macular Degeneration (AMD) | Phase 3 | Withdrawn | Novartis Pharmaceuticals | 2021-05-31 | 2021-09-23 | |
| Characteristics of Patients With Neovascular Age-related Macular Degeneration Enrolled in the Brolucizumab Patient Support Services Program All participants - Age-related Macular Degeneration (AMD) | Completed | Novartis Pharmaceuticals | 18457 | 2020-08-11 | 2021-10-12 | |
| Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry) Aflibercept, Ranibizumab, Bevacizumab - Age-related Macular Degeneration (AMD) | Completed | Novartis Pharmaceuticals | 331541 | 2020-07-15 | 2021-12-21 | |
| Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health) Aflibercept, Ranibizumab, Bevacizumab - Age-related Macular Degeneration (AMD) | Completed | Novartis Pharmaceuticals | 369600 | 2020-07-15 | 2021-12-16 |
Showing 20 of 37. Sign in to see all of them.
Macular Degeneration (37) · Diabetic Retinopathy (7) · Retinal Vein Occlusion (3) · Alzheimer Disease (1) · Choroidal Neovascularization (1) · Eye Diseases (1) · Geographic Atrophy (1) · Glaucoma (1) · Macular Degeneration, Age-Related, 10 (1) · Macular Edema (1) · Musculoskeletal Pain (1) · Retinal Degeneration (1) · Retinal Detachment (1) · Retinal Diseases (1) · Shoulder Pain (1)
Eye Diseases (36) · Retinal Degeneration (36) · Retinal Diseases (36) · Cardiovascular Diseases (8) · Vascular Diseases (8) · Diabetes Complications (7) · Diabetes Mellitus (7) · Diabetic Angiopathies (7) · Endocrine System Diseases (7) · Embolism and Thrombosis (3) · Thrombosis (3) · Venous Thrombosis (3) · Nervous System Diseases (2) · Pathological Conditions, Signs and Symptoms (2) · Uveal Diseases (2)
Ranibizumab (6) · aflibercept (5) · brolucizumab (4) · Bevacizumab (3) · Off-Label Use (2) · Blood Specimen Collection (1) · Cocaine (1) · Diet, Ketogenic (1) · Dimethyl Fumarate (1) · Interviews as Topic (1) · Lidocaine (1) · Low-Level Light Therapy (1) · Observation (1) · Tetracaine (1) · Therapeutics (1)
Novartis Pharmaceuticals (7) · National Taiwan University Hospital (2) · Alcon Research (1) · Assistance Publique - Hôpitaux de Paris (1) · Assiut University (1) · Bayer (1) · Beni-Suef University (1) · Bioeq GmbH (1) · Bristlecone Health, Inc. (1) · Centre Hospitalier Universitaire, Amiens (1) · Doheny Image Reading Center (1) · Eyetech Pharmaceuticals (1) · Fondazione G.B. Bietti, IRCCS (1) · Harrow Inc (1) · IRCCS San Raffaele (1)
United States (19) · France (5) · Italy (4) · United Kingdom (4) · Canada (3) · Germany (3) · Israel (3) · Austria (2) · Hungary (2) · Poland (2) · Spain (2) · Taiwan (2) · Australia (1) · Czechia (1) · Egypt (1)
Alauddin Bhuiyan, PhD (1) · Alessandro Arrigo, MD, PhD (1) · Ali Natag Ryad, professor (1) · Daniel E Salazar, PhD (1) · E J Johnson, PhD (1) · Florian M Heussen, Dr. med. (1) · Frank G. Holz, Prof. Dr. (1) · Hatice N Sen, M.D. (1) · Jay Hegde, PhD (1)
PMID 20472746, PMID 20547953, PMID 21144031, PMID 22559899, PMID 23332590, PMID 24385141, PMID 25104651, PMID 28906084, PMID 30303083, PMID 31757502, PMID 33958600, PMID 37702300, PMID 39918524, PMID 40682000, PMID 42406913
2014 (1), 2019 (1), 2023 (1), I21RX004099 (1), R44EY031202 (1)